Synthesis of 17β-hydroxy-des-A-androst-9,10-en-5-one via Chiral Starting Material
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing 17β-hydroxy-des-A-androst-9,10-en-5-one, an intermediate for retroprogesterones, are inefficient and not industrially scalable due to the use of racemic reagents and low yields from separation of optical antipodes, which limits the production of optically pure compounds for pharmaceutical use.
Innovation Solution
A process involving the reaction of (4aR,6aS,9aS,9bS)-decahydro-6a-methyl-cyclopenta[f][1]benzopyran-3,7-dione with ethylmagnesium bromide or chloride, followed by oxidation and cyclization, to produce 17β-hydroxy-des-A-androst-9,10-en-5-one, which eliminates the need for racemic reagent separation and enhances yield.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If racemic reagents are used and optical antipodes are separated, then optically pure compound can be obtained, but yield is reduced to maximum 50% due to separation loss
Solution Approach 1:
Instead of starting with a racemic mixture and separating the antipodes (which loses 50% material), the invention inverts the approach by using a chiral starting material ((4aR,6aS,9aS,9bS)-decahydro-6a-methyl-cyclopenta[f][1]benzopyran-3,7-dione) that directly produces the desired optical isomer through asymmetric synthesis, eliminating the need for separation and maximizing yield
Solution Approach 2:
The invention introduces chirality at the very beginning of the synthesis pathway by selecting a chiral starting material with defined stereochemistry. This preliminary establishment of optical purity propagates through all subsequent reaction steps, ensuring the final product maintains optical purity without requiring intermediate separations
2Manufacturing precision
If multiple chemical reactions and separation steps are used, then optically pure compound can be obtained, but synthesis complexity increases
Solution Approach 1:
The invention simplifies the synthesis pathway by inverting the conventional approach: rather than creating a racemate and then separating it through multiple steps (including salification with chiral amines and filtration), the method uses a chiral starting material that directly yields the optically active product through a streamlined sequence of reactions
Solution Approach 2:
The invention extracts the complexity of optical resolution from the synthesis pathway by eliminating the need for separation steps entirely. By using asymmetric synthesis from a chiral starting material, the method removes the cumbersome procedures of racemate separation, washing, and purification that characterize conventional approaches
3Ease of manufacture
If conventional synthesis routes are used, then retroprogesterones can be prepared, but material loss increases due to resolution of racemates
Solution Approach 1:
The invention inverts the conventional wisdom of starting with readily available racemic precursors. By reversing the approach and beginning with a chiral material, the method eliminates the inherent 50% material loss that occurs when resolving racemates, thereby improving overall material efficiency while maintaining ease of manufacture
Solution Approach 2:
The invention changes the stereochemical parameter of the starting material from racemic (achiral) to optically active (chiral). This parameter change propagates through the synthesis, ensuring that all intermediate and final products maintain the desired stereochemistry without requiring material-intensive separation processes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method simplifies the synthesis of 17β-hydroxy-des-A-androst-9,10-en-5-one, allowing for an industrially applicable and more efficient production of optically pure intermediates for retroprogesterones, improving yield and reducing material loss.
Implementation Method 1
reaction of compound (4aR,6aS,9aS,9bS)-decahydro-6a-methyl-cyclopenta[f][1]benzopyran-3,7-dione, compound (II), with ethylmagnesium bromide or ethylmagnesium chloride to give the isomer mixture (4S,5R,7aS)-5-hydroxy-7a-methyl-4-(3-oxopentyl)octahydro-1H-inden-1-one and (4S,5S,7aS)-5-hydroxy-7a-methyl-4-(3-oxopentyl)octahydro-1H-inden-1-one, intermediate mixture (III)
Implementation Method 2
oxidation of the intermediate mixture (III) to give (4S,7aS)-7a-methyl-4-(3-oxopentyl)hexahydro-1H-inden-1,5(4H)-dione, intermediate (IV)
Implementation Method 3
cyclization of the intermediate (IV) to give des-A-androst-9,10-en-5,17-dione, intermediate (V)
Implementation Method 4
reduction of the intermediate (V) to 17β-hydroxy-des-A-androst-9,10-en-5-one (1)
Data Source
AI summary
The present invention relates to a new process for the synthesis of 17β-hydroxy-des-A-androst-9,10-en-5-one, the compound of the following formula (1), which can be used as an intermediate in the synthesis of retroprogesterones.